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vaccine aimed to reduce disease caused by S. Typhi and S. Paratyphi
A.15th ICID Abstracts / International Journa
ia, 35% fever and 17% headache. More females reported AEFI than
ales (58% vs 42%, p <0.01). Persons aged 20-29 reported the high-
st proportion of AEFI (9.3%). Univariate analysis detected that drug
llergies (OR=3.1, CI [1.0-8.1]) and receiving tetanus vaccine in
he prior three months (OR=4.5, CI [2.8-7.5]) were associated with
EFI. Vaccine demand exceeded supply and 98% of vaccinees stated
hat they would like to receive annual inﬂuenza vaccination.
Conclusion: This study detected many more AEFI than the
ational passive AEFI surveillance system showing a need for
mprovements. Awareness about AEFI should be raised by health
are workers so that vaccinees are sensitized to seek immediate
edical care. Follow up surveys should be included with future
accination campaigns until the passive surveillance is improved.
he acceptability and demand for inﬂuenza vaccinemake a case for
uture targeted inﬂuenza vaccination campaigns in Laos.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.1001
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nvasive pneumococcal disease: impact of pneumococcal vacci-
ation in South Australian children
. Tran, M. Clarke, H. Marshall ∗
Vaccinology & Immunology Research Trials Unit, Adelaide, South
ustralia, Australia
Background: Streptococcus pneumoniae (pneumococcus) causes
nvasive pneumococcal disease (IPD) worldwide resulting in more
eaths than any other vaccine preventable disease. The rates of
PD in indigenous children in Australia have been the highest in
he world, even when compared with other indigenous groups.
hildren <2 years of age are at increased risk of severe disease
nd potentially serious sequelae. In 2005, a 7-valent pneumococcal
onjugate vaccine (7vPCV) was introduced within the Australian
ational Immunisation Program.
Methods: This cross-sectional study compared the causative
neumococcal serotypes and IPD-associated complications before
nd after introduction of 7vPCV in children admitted to the
omen’s & Children’s Hospital, South Australia. Pneumococcal
erotypes were identiﬁed from culture conﬁrmed cases. Admission
etails and complications were captured using a data collection
uestionnaire. Disease severity was measured using a modiﬁed
aediatric Logistic OrganDysfunction (PELOD) score. Datawas ana-
ysed using the Pearson chi-squared test.
Results: Between 2000-2010, 145 cases of IPD were identiﬁed,
f which 116 were serotyped. 7vPCV serotypes caused 87% (59/68)
f serotyped cases prior to introduction of the vaccine compared
o 21% (10/48) following introduction of 7vPCV (p<0.001). How-
ver non-7vPCV serotype cases have increased. Serotype 19A has
merged as a major cause of IPD (3/68 cases before versus 20/48
ases after 7vPCV was widely available).
IPDcasesdue tonon-7vPCVserotypesweremore likely to report
omplications (p <0.025). There were 3 cases of IPD reported to
e complicated by empyema before 7vPCV was widely available
ompared to 10 cases after the vaccine was introduced. IPD-
elated empyema was also associated with admission to the high
ependency/intensive care unit (p <0.001). Pericarditis (n =1) andfectious Diseases 16S (2012) e158–e316 e309
haemolytic uraemic syndrome (n=1) associated with IPD was also
reported in cases following 7vPCV introduction.
Non-7vPCV serotypes may be associated with more severe dis-
ease (p =0.05).
Conclusion: The reduction in IPD caused by PCV7 serotypes
is partly offset by an increase in non-7vPCV serotype disease.
Non-7vPCVserotypedisease is associatedwithmore reported com-
plications. Predominant circulating serotypes may impact disease
severity.
http://dx.doi.org/10.1016/j.ijid.2012.05.1002
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Development of conjugate vaccines for enteric fever
L. Martin ∗, V. Di Cioccio, A. Saul, A. Podda
Novartis Vaccines Institute for Global Health, Sienna, Italy
Background: The implementation of conjugate vaccines has
made a signiﬁcant impact on the burden of bacterial disease in
both developing and developed countries. Enteric fever causes >25
million cases of disease yearly worldwide, with more than 90%
of the disease burden reported in Asia. In this region, protein-
polysaccharide conjugate vaccines have potential to reduce disease
caused by Salmonella enterica serovars Typhi and Paratyphi A, in all
age groups but particularly the very young. The Novartis Vaccines
Institute for Global Health (NVGH) has developed Vi-CRM197, a
conjugate vaccine against S. Typhi. Based on recent surveillance
data from south Asia, up to 50% of enteric fever cases are caused
by S. Paratyphi A, and thus NVGH is also working to augment Vi-
CRM197 by the addition of a component speciﬁc to S. Paratyphi A,
the O-speciﬁc polysaccharide (O:2), conjugated to CRM197.
Methods: Vi-CRM197 was evaluated in European clinical trials,
and is currently being evaluated in endemic populations. A novel
method for O-antigen extraction directly from bacteria culture and
for its puriﬁcation and conjugation has been developed. The O:2-
CRM197 conjugate alone or formulated with Vi-CRM197 has been
tested for immunogenicity in mice.
Results: Vi-CRM197 was highly immunogenic in humans,
inducing higher Vi speciﬁc antibody levels compared to Vi polysac-
charide control. The process development of O:2-CRM197 has
resulted in a reproducible and scalable method for manufacture.
O:2 conjugate alone or in combination with Vi-CRM197 induced
high levels of serum anti-O:2 IgG following immunization of mice.
These anti-O:2 containing sera possess potent bactericidal activity
against S. Paratyphi A in vitro. No immunologic interference was
observed in the levels of anti-Vi, anti-O:2 or serum bactericidal
activity in animals immunized with the bivalent combination.
Conclusion: Work is ongoing to further characterize the
immune responses generated by the bivalent vaccine (Vi-
CRM197+O:2-CRM197) to further support its development. The
current data demonstrates important attributes of NVHG’s bivalenthttp://dx.doi.org/10.1016/j.ijid.2012.05.1003
